The Latest

  • tangled knot between two businessmen walking a tightrope
    Image attribution tooltip
    Cemile Bingol via Getty Images
    Image attribution tooltip

    The fortunes and flops of pharma M&A

    Hindsight offers a better perspective on why some deals are fruitful and others fail.

  • dollar sign airplane
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The weight loss market looks unstoppable. How high could it go?

    Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

  • idea pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 standout digital innovations in pharma this year

    IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.

  • Portrait of John Mulligan, chief executive officer of Bonum.
    Image attribution tooltip
    Permission granted by Bonum Therapeutics
    Image attribution tooltip

    How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times

    John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.

  • brain maze
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help

    A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.

  • A printed copy of the 2017 Tax Cut and Jobs Act is seen lying on a desk with other papers.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip
    Deep Dive

    Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

    U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

  • Cristina Durán, president, Evinova
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip
    Q&A

    The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

    Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.

  • Header image for "Creating a Compelling IPO Roadshow Presentation"
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Biopharma’s top 5 IPOs of 2023 (so far)

    Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

  • alcohol bottles illustration
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As alcohol-related deaths climb, new drugs could curb the urge to drink

    A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

  • Dr. Victoria Zazulina, global head of oncology development, EMD Serono
    Image attribution tooltip
    Permission granted by EMD Serono
    Image attribution tooltip

    How EMD Serono plans to hit its lofty goals in R&D

    The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.

  • Dr. Juan Camilo Arjona Ferreira, chief medical officer, Organon
    Image attribution tooltip
    Permission granted by Organon
    Image attribution tooltip
    Q&A // First 90 Days

    Organon’s chief medical officer wants to change how the world sees women’s health

    Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.

  • COO, chief operating officer
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The biopharma COO’s playbook

    Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

  • body muscle
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

    Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

  • man in dark tunnel
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    ​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

    The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

  • Janet Woodcock in senate
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    Top FDA official Woodcock to retire early next year

    The 37-year veteran helmed the agency’s pandemic response, and was a key decision-maker in controversial calls on opioids, an Alzheimer's therapy and muscular dystrophy drugs.

  • Dr. Paul Moss, deputy head, College of Medical and Dental Sciences, Professor of Haematology, University of Birmingham
    Image attribution tooltip
    Permission granted by AstraZeneca/U. of Birmingham
    Image attribution tooltip
    Q&A

    AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

    Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

  • Genomics DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The power of genomics-based healthcare remains largely untapped

    23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

  • Lindsay Pino, co-founder, chief technology officer, Talus Bio
    Image attribution tooltip
    Permission granted by Talus Bio
    Image attribution tooltip
    Biotech Spotlight

    A biotech tackles drug discovery with transcription factor know-how

    Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

  • Denise Bronner headshot
    Image attribution tooltip
    Permission granted by Johnson & Johnson Innovative Medicine
    Image attribution tooltip

    6 ways to improve clinical trial diversity — as shown by J&J

    Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Can Sarepta’s Duchenne gene therapy still deliver on its promise?

    For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.

  • moquito art
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

    The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

  • ceo pay
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 of the best paid biopharma CEOs

    As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

  • 2023 Red Jacket header
    Image attribution tooltip

    Photo illustration: Industry Dive

    Image attribution tooltip

    The 2023 Red Jacket honorees

    This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

  • Jean Jacques Bienaime headshot
    Image attribution tooltip
    Permission granted by BioMarin
    Image attribution tooltip
    Making Moves

    Does BioMarin’s CEO shuffle signal bigger changes ahead?

    With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.

  • A scale is foregrounded against the sky.
    Image attribution tooltip
    zennie via Getty Images
    Image attribution tooltip

    How pharma leaders talk about ethics in a highly criticized industry

    The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?